The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: A 30-year follow-up
| Autor: | Kristina H. Haugaa, Cecilie E. Kiserud, Thor Edvardsen, Ragnhild V. Nome, Hege Sagstuen Haugnes, A W Bjerring, Thomas M. Stokke, Sophie D. Fosså, Sebastian I. Sarvari |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Cardiac function curve medicine.medical_specialty Diastole 030204 cardiovascular system & hematology Coronary artery disease 03 medical and health sciences 0302 clinical medicine Testicular Neoplasms Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Survivors Systole Testicular cancer Aged Norway business.industry valvular heart disease VDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710 General Medicine Middle Aged medicine.disease Chemotherapy regimen VDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710 Blood pressure 030220 oncology & carcinogenesis Cardiology Cisplatin Cardiology and Cardiovascular Medicine business Follow-Up Studies |
| ISSN: | 2047-2404 |
| Popis: | Aims Cisplatin-based chemotherapy (CBCT) is essential in the treatment of metastatic testicular cancer (TC) but has been associated with long-term risk of cardiovascular morbidity and mortality. Furthermore, cisplatin can be detected in the body decades after treatment. We aimed to evaluate the long-term impact of CBCT on cardiac function and morphology in TC survivors 30 years after treatment. Methods and results TC survivors treated with CBCT (1980–94) were recruited from the longitudinal Norwegian Cancer Study in Testicular Cancer Survivors and compared with a control group matched for sex, age, smoking status, and heredity for coronary artery disease. All participants underwent laboratory tests, blood pressure measurement, and 2D and 3D echocardiography including 2D speckle-tracking strain analyses. Ninety-four TC survivors, on average 60 ± 9 years old, received a median cumulative cisplatin dose of 780 mg (IQR 600–800). Compared with controls, TC survivors more frequently used anti-hypertensive (55% vs. 24%, P Conclusion No signs of overt or subclinical reduction in systolic function were identified. Long-term cardiovascular adverse effects three decades after CBCT may be limited to metabolic dysfunction and worse diastolic function in TC survivors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|